Conversely, analysis of DVL3 by IHC has indicated DVL3 expression does not correlate with tumor stage, grade or survival in prostate and breast cancers [86], and homozygous deletion of DVL1 and DVL2 has also been observed in primary and metastatic prostate cancer (up to 6.8% and 4.3% incidence respectively, Tables S1–S4), and these events appear to be mutually exclusive (Figures S1–S4). This evidence concerns the gene DVL3 and breast carcinoma.